The Specific Role of Isoflavones in Reducing Prostate Cancer Risk

• ClinicalTrials.gov Identifier: NCT00617617
• Recruitment Status: Completed
• First Posted: February 18, 2008
• Last Update Posted: September 24, 2012
• Sponsor: H. Lee Moffitt Cancer Center and Research Institute
• Collaborator: Cognis
• Information provided by (Responsible Party): H. Lee Moffitt Cancer Center and Research Institute

Tracking Information

• First Submitted Date: February 5, 2008
• First Posted Date: February 18, 2008
• Last Update Posted Date: September 24, 2012
• Study Start Date: February 2002
• Actual Primary Completion Date: May 2007 (Final data collection date for primary outcome measure)
• Current Primary Outcome Measures (submitted: February 5, 2008): Observe the effects of the 12 - week intervention with isoflavones on sex hormones and PSA, a marker of disease progression. [ Time Frame: 12 week treatments ]
• Original Primary Outcome Measures: Same as current
• Current Secondary Outcome Measures: Not Provided
• Original Secondary Outcome Measures: Not Provided
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: The Specific Role of Isoflavones in Reducing Prostate Cancer Risk
• Official Title: The Specific Role of Isoflavones in Reducing Prostate Cancer Risk
• Brief Summary: The purpose of this research study is to determine if giving men with early stage (Grade 1-2) prostate cancer dietary supplement from soybeans called isoflavones, will change their blood hormone levels. Isoflavones are substances found in a high concentration in soybeans that are converted in the intestines to hormone-like compounds which are similar to estrogen. They are also thought to have cancer fighting properties. Clinical trials suggest that isoflavones can increase certain sex hormones, which results in the slower production of prostate cancer cells. This study will determine if adding isoflavones (supplied as Prevastein HC®) 80 mg/day in a pill form can change your risk factors that cause early stage prostate cancer to progress to more advanced disease.

Detailed Description

To prevent biasing the outcome of the study, this is a double-blind study design, where both the trialists and the participants are blinded to the specific nature of the product (isoflavones and placebo). Participants in both groups will be discouraged from increasing their intake of dietary isoflavones in the form of tofu, soy beans, soy milk, etc. In addition, the intervention does not include active counseling on dietary modification and supplementation of any one group. Monthly appointments will be made for all participants for data collection and toxicity assessment.

Schema:

This is a controlled, randomized, double blinded clinical trial, having one experimental and one control group (n - 75/arm). Participants in the experimental group will consume an isoflavones supplement in the form of Prevastein HC®, which will deliver 80 mgs (40 mg/dose) biologically active isoflavones and those in the control group will receive an identical placebo. The isoflavones supplement and the placebo tablets will be manufactured and packaged by Cognis Corporation.

1. Isoflavones will be supplied at no charge by Cognis Corporation, LaGrange, Illinois as Prevastein HC®. Each Prevastein HC® tablet delivers 20 mg biologically active isoflavones, which is available for absorption. Participants will consume 2 tablets twice daily (with meals) in addition to their usual diet.
2. Placebo will be supplied at no charge by Cognis Corporation, LaGrange, Illinois as an indistinguishable tablet. Participants will consume 2 tablets twice daily (with meals) in addition to their usual diet.
3. A standardized multivitamin will be supplied at no charge.

• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Triple (Participant, Care Provider, Investigator); Primary Purpose: Prevention
• Condition: Prostate Cancer

Intervention

• Dietary Supplement: Prevastein HC®
  Experimental Group - Participants in the experimental group will consume an isoflavones supplement in the form of Prevastein HC®, which will deliver 80 mgs (40 mg/dose) biologically active isoflavones.
• Other: Placebo
  Control Group - Control Group participants will receive an identical placebo.

Study Arms

• Experimental: A
  Dietary Supplement: Prevastein HC®
  Intervention: Dietary Supplement: Prevastein HC®
• Placebo Comparator: B
  Placebo
  Intervention: Other: Placebo

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: February 10, 2010): 52
• Original Estimated Enrollment (submitted: February 5, 2008): 56
• Actual Study Completion Date: May 2007
• Actual Primary Completion Date: May 2007 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Males, between the ages of 50 and 80
• Diagnosed with grade 1-2 prostate cancer (Gleason Score 2 to 6) Note: patients with a Gleason primary pattern 4 (4+1 or 4+2) are not eligible.
• No prior or current therapy for prostate cancer
• No other history of cancer except non-melanoma skin cancer
• No known history of hepatic and/or renal disease
• No evidence of prostatitis or urinary tract infection (men being treated with antibiotics may be enrolled 30 days after completion of therapy given that they still meet all other eligibility criteria)
• No antibiotic use within 30 days of registration
• Close to ideal body weight(Body Mass Index no greater than 32 Kg/m²)
• Omnivorous diet
• Able and willing to give written consent

Exclusion Criteria:

• Less than 50 years or over 80 years of age
• Prostate cancer beyond grade 2 (Gleason Score greater than 6)
• Gleason primary pattern 4 (4+1 or 4+2)
• Prior or planned treatment for prostate cancer of any stage
• Prior history of other cancer except non-melanoma skin cancer
• Current use of nutritional supplements, including modular supplements of other agents with antioxidant properties e.g. retinoids, beta-carotene, and isoflavones
• Allergy to study agent
• Known history of hepatic or renal disease
• Body Mass Index greater than 32 Kg/m²
• Vegetarian/vegan diet
• Diet high in soy products (men who routinely consume a diet high in soy products may be enrolled 30 days after eliminating soy product from the diet)
• Prostatitis or urinary tract infection
• Treatment with antibiotics within 30 days of registration

Sex/Gender

• Sexes Eligible for Study: Male

• Ages: 50 Years to 80 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT00617617
• Other Study ID Numbers: MCC-12835; NCI #4031; CA 81920
• Has Data Monitoring Committee: No
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: H. Lee Moffitt Cancer Center and Research Institute
• Original Responsible Party: Nagi B. Kumar, PhD., R.D., FADA, H. Lee Moffitt Cancer Center and Research Institute
• Current Study Sponsor: H. Lee Moffitt Cancer Center and Research Institute
• Original Study Sponsor: Same as current
• Collaborators: Cognis

Investigators

• Principal Investigator: Nagi B. Kumar, PhD., RD; H. Lee Moffitt Cancer Center and Research Institute

• PRS Account: H. Lee Moffitt Cancer Center and Research Institute
• Verification Date: February 2010